Testing version — LOERadar is in active testing. Features and data may change.
CAPOTEN (CAPTOPRIL) | LOERadar
CAPOTEN
NDA
CAPTOPRIL | N018343 | AARXION ANDA HOLDING LLC
7 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (7)
Sort:
#001 — 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
No patent or exclusivity listings for this strength.
#002 — 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#003 — 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982
#004 — 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Jun 13, 1995
#005 — 12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Jan 17, 1985
#006 — 37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Sep 17, 1986
#007 — 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**